Morice P, Brehier-Ollive D, Rey A, Atallah D, Lhommé C, Pautier P, Pomel C, Camatte S, Duvillard P, Castaigne D
Department of Surgery, Institut Gustave Roussy, Villejuif, France.
Ann Oncol. 2003 Jan;14(1):74-7. doi: 10.1093/annonc/mdg003.
To study the results of interval debulking surgery (IDS) in patients treated for 'unresectable' advanced stage ovarian cancer compared with primary debulking surgery (PDS) followed by chemotherapy.
An exposed-non-exposed study including a group of 34 patients who underwent an IDS and were matched to an historic control group of 34 patients treated with PDS.
Optimal cytoreductive surgery was achieved in 94% (32 out of 34) of patients in both groups. The rates of post-operative morbidity, blood transfusion and median length of hospitalisation were significantly reduced in the study (IDS) group, but survival did not differ in both groups.
IDS in patients with advanced stage ovarian cancer offers the same chance of survival as PDS, but it is better tolerated.
研究间隔肿瘤细胞减灭术（IDS）用于治疗“无法切除”的晚期卵巢癌患者的结果，并与先进行肿瘤细胞减灭术（PDS）再进行化疗的患者进行比较。
一项暴露-非暴露研究，包括一组34例行IDS的患者，并与34例接受PDS治疗的历史对照组患者进行匹配。
两组中94%（34例中的32例）的患者实现了最佳细胞减灭术。研究（IDS）组术后发病率、输血率和中位住院时间显著降低，但两组生存率无差异。
晚期卵巢癌患者行IDS与PDS的生存机会相同，但耐受性更好。
